Chardan raised the firm's price target on CervoMed to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully back on track following alignment reached with the FDA in November 2025 for a Phase 3 registrational study in dementia with Lewy bodies, the analyst tells investors in a research note. With strong efficacy data with the new neflamapimod product batch in the completed Phase 2 study and with alignment on patient selection, a new drug formulation reaching desired drug plasma levels, and a new higher dose in the planned Phase 3 study, the firm is increasingly confident in the successful outcome of the DLB program.
